Planned subscription platform expands CATS’ focus from measuring eye pressure to helping clinicians
interpret risk and explore treatment scenarios.
TUCSON, Ariz. — [09-Nov-2026] — CATS Tonometer, LLC is developing an AI-enabled glaucoma
software service that builds on its FDA-cleared tonometer prism and peer-reviewed research in
intraocular pressure measurement, optic nerve structural loss, and pressure-response modeling.
The planned subscription service brings together three complementary capabilities: retinal nerve fiber
layer (RNFL) and pressure reference charts, multifactor assessments of glaucoma onset and progression
risk, and treatment-scenario comparisons using published intraocular pressure equations. The goal is to
help clinicians place pressure measurements within a broader, patient-specific picture of glaucoma risk
and management.
The initiative represents a planned expansion of CATS from ophthalmic measurement technology into
recurring-revenue clinical software, creating opportunities for strategic collaboration across ophthalmic
devices, diagnostics, therapeutics, and digital health.
A published scientific foundation
The CATS Tonometer Prism is an FDA-cleared replacement prism for Goldmann-type tonometers,
designed to reduce measurement errors associated with corneal properties and tear-film effects. Its
scientific foundation includes peer-reviewed engineering studies, direct comparisons with intracameral
pressure, and multicenter randomized clinical trials.
That research has extended beyond measurement accuracy to the relationship between measured
pressure and glaucoma damage. A 2025 study in BMC Ophthalmology reported a stronger association
between CATS modified-prism pressure measurements and progressive RNFL thinning than between
standard Goldmann measurements and thinning. The findings support further investigation of how
pressure measurement can inform assessment of structural loss.
Separately, Sean McCafferty and John Berdahl published intraocular pressure equations in Clinical
Ophthalmology in 2025. Their work models both steady-state pressure and changes over time using
aqueous-fluid flow relationships, providing a published mathematical foundation for the service’s
pressure-response scenarios.
From measurement to a broader glaucoma service
Prototype charting and risk-assessment tools are being developed for in-house use. The planned service
would allow clinicians to compare pressure and RNFL trends, review multiple contributors to glaucoma
risk, and explore modeled pressure responses to potential interventions.
AI-assisted development and evidence review are intended to support ongoing refinement as new
research and appropriately governed patient-outcome data become available. Clinician-facing models
are planned as dated, version-controlled releases with transparent factor contributions, rather than
equations that change invisibly during use.
The software remains under development. Published evidence supporting CATS measurement and the
IOP equations is distinct from validation of the integrated service; the prism’s FDA clearance does not
extend to the planned software.
CATS welcomes discussions with clinical collaborators and strategic industry partners interested in
connecting pressure measurement, predictive modeling, and longitudinal glaucoma care.
About CATS Tonometer
CATS Tonometer, LLC develops ophthalmic pressure-measurement technology. Its CATS Tonometer
Prism is FDA-cleared for measuring intraocular pressure with Goldmann-type tonometers. The
company’s research is available through its peer-reviewed publications.
Media and strategic inquiries:
Early Signal Diagnostics Corp.
www.earlysignaldiagnostics.com


